Thursday, 5 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Investor Presentation

NCC Investor Presentation: Key Takeaways

Q2 FY27 consolidated revenue ₹6,042 Cr (+32%), EBITDA ₹528 Cr (8.79% margin), PAT ₹184 Cr (+19%); order book ₹80,167 Cr.

Highlights
Revenue growthConsolidated Q2 +32% YoY; H1 +21%
MarginsConsolidated Q2 EBITDA margin 8.79%, down 59 bps QoQ
Order bookStandalone ₹71,293 Cr; consolidated ₹80,167 Cr
Demand visibilityOrder book ₹80,167 Cr, +11% YoY

Growth

H1 consolidated revenue ₹11,884 Cr (+21%); PAT ₹401 Cr (+16%). Standalone Q2 EBITDA +50% YoY.

Outlook

No explicit growth guidance. Order book ₹80,167 Cr; smart-metering contracts ₹8,080 Cr, ~8 mn meters.

Risks

Standalone H1 CFO ₹138 Cr vs PAT ₹350 Cr; consolidated net debt rose to ₹3,887 Cr from ₹2,815 Cr.

Last quarter's promises, checked

Delivered

  • Guided FY27 revenue growth 8–10% → H1 consolidated revenue +21% (= BEAT)

Partly delivered

  • Guided FY27 EBITDA margin 8.5–9% → Q2 consolidated 8.79%, in band; single quarter (= PARTIAL)
  • Guided FY27 order inflow ₹22,000–25,000 cr → Q1 inflow ₹3,889 cr; H1 not disclosed (= PARTIAL)
  • Guided FY27 capex ₹500 cr → Q1 spend ₹170 cr; H1 not disclosed (= PARTIAL)

Missed

  • Guided standalone debt flat at ~₹2,410 cr through Mar-27 → consolidated net debt ₹3,513 cr (Jun) rose to ₹3,887 cr (Q2); standalone Q2 not disclosed (= MISS)
Source

Investor Presentation filed with BSE, NSE: NCC. Summary written with AI assistance from the document.

Read the document ↗

NCC Ltd: key numbers

Share price
₹122.60
Market cap
₹7,697 Cr
Revenue (annual)
₹20,823 Cr
Net profit (annual)
₹675.3 Cr
P/E (TTM)
11.0×Sector 32.7×
Promoter holding
23.19%+0.11% QoQ
FII holding
10.44%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from NCC Ltd

All →
19:38 IST BSE
Management Change

NCC Management Change

NCC Limited re-appointed three executive directors, A V Ranga Raju Alluri as MD and two Whole-time Directors, effective 1 April 2027 for 60 months. Only a board-level leadership renewal is disclosed, with no financial amount.

Execution
Re-appointment term of 60 months from 2027-04-01